Showing 281-290 of 353 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Determining how NKG2D signaling drives autoimmune diabetes | University of Kansas Medical Center Research Institute, Inc. | Mary Markiewicz | Cures | 01-September-2023 to 31-August-2026 | $750,000.00 |
| Engineering a novel Treg population to control autoimmune diabetes | University of Kansas Medical Center Research Institute, Inc. | Mary Markiewicz | Cures | 01-April-2025 to 31-December-2026 | $199,999.62 |
| Achieving immune protection in islet transplantation by combining peptide-loaded nanoparticles with conformal coating of islets | University of Kansas Medical Center Research Institute, Inc. | Hubert Tse | Cures | 01-April-2024 to 30-November-2026 | $599,998.25 |
| NKG2D Signaling as a Critical Modulator of Autoreactive CD8⁺ T Cell Differentiation and β Cell Destruction in Type 1 Diabetes | University of Kansas Medical Center Research Institute, Inc. | Ambika Dudhate | Cures | 01-March-2026 to 28-February-2029 | $274,010.00 |
| Defining the target product profile of intra-lymph node depots as a durable antigen-specific immunotherapy for T1D | University of Maryland | Christopher Jewell | Cures | 01-April-2026 to 31-March-2029 | $1,199,997.36 |
| Artificial Intelligence-driven redesign of beta cell regulatory logic for resilience to inflammation | University of Massachusetts Medical School | Rene Maehr | Cures | 01-April-2026 to 31-March-2027 | $199,999.88 |
| In vivo interactions and trafficking of islet antigen-specific human effector T cells and Tregs | University of Massachusetts Medical School | Michael Brehm | Cures | 01-November-2024 to 31-October-2027 | $825,000.00 |
| Interrogation of FBR immunity using novel humanized mice | University of Massachusetts Medical School | Michael Brehm | Cures | 01-October-2026 to 30-September-2027 | $300,000.00 |
| A Cure for Type 1 Diabetes | University of Massachusetts Medical School | David Harlan | Cures | 01-October-2025 to 30-September-2029 | $16,000,000.00 |
| mIL-2/CD25 fusion protein and BTK inhibitor combination therapy for T1D | University of Miami | Wasif Khan | Cures | 01-May-2023 to 30-April-2027 | $974,996.00 |